Could growth hormone be linked to Alzheimer's transmission? Read the latest study unraveling the signs and implications. Knowledge is power! https://lnkd.in/gmaBAgW9 Nature #medical #research #alzheimers #study #research
Research Square’s Post
More Relevant Posts
-
[INNOVATION UPDATE] A new experimental, noninvasive treatment for Alzheimer’s disease is showing promising outcomes. The GammaSense Stimulation system (CogTx-001) is an experimental, noninvasive sensory stimulation device being investigated to treat mild to moderate Alzheimer’s. It is designed to slow cognitive decline by increasing a type of electrical activity in the brain that is typically diminished in patients with the disease. CogTx-001 reportedly achieved significant changes in activities of daily living, and brain atrophy, without serious safety concerns. The only currently approved treatment for Alzheimer's carries a risk of a serious adverse event. There is a significant need for safe and effective treatments. Learn more about CogTx-001 in today’s Emerging Health Care Innovation Brief: https://hubs.la/Q02cvVZC0 hashtag #alzheimersdisease hashtag #neurology hashtag #patientcare hashtag #healthcare hashtag #innovation hashtag #horizonscanning hashtag #ECRI
To view or add a comment, sign in
-
Neurodegenerative disorders affect around 44 million people worldwide and cost the healthcare industry billions each year. Early detection allows for quicker action, reducing effects on the patient and healthcare system as much as possible.🏥 Western University researchers have created a technique that incorporates a machine learning algorithm to detect early disease changes within the brain, allowing treatment interventions before the progression of neurodegeneration. It also reduces radiation risks compared with the use of radioactive tracers in current neurological disorder diagnostics.🧠 #medicaljobs #HealthcareJobs #MedicalCareer #vacancies #medicalfield #medicalstaff #recruitment #healthcare #MedicalRecruitment #technologies #medicaltechnology #neurodegenerative #diseases
To view or add a comment, sign in
-
1. A recent study identified two new potential risk factors for Alzheimer's: untreated vision loss and high LDL cholesterol. 2. The study was published in The Lancet and involved 26 researchers from various universities and health systems. 3. Previous known risk factors included lower education, hearing loss, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, and social isolation. 4. Vision loss may hinder sensory input, reducing the brain's information processing and limiting engagement in physical and social activities. 5. High LDL cholesterol could negatively affect heart and blood vessel health, which is crucial for optimal brain function. 6. Regular health checkups are recommended to manage these risk factors effectively. 7. Keeping the brain active through reading, puzzles, and continuous learning is essential for reducing Alzheimer's risk. 8. Diet and exercise are highlighted as important components of overall health and Alzheimer's prevention.
New Study: Neglecting These 2 Issues May Increase Alzheimer's Risk — The Healthy
apple.news
To view or add a comment, sign in
-
More than a wonder drug: Viagra linked to better brain function The research conducted by scientists at the University of Oxford, the results of which appeared in journal Circulation Research, represents a significant advancement in the battle against dementia. The findings could provide a crucial turning point in the efforts to combat the disease, said city doctors. #Wonder | #Viagra | #Brainfunction | #Scientists | #Universityofoxford | #Journal | #CirculationResearch | #Significant | #Advancement | #Dementia | #Citydoctors | #Disease | #Healthnews Read more:
More than a wonder drug: Viagra linked to better brain function - ET HealthWorld
health.economictimes.indiatimes.com
To view or add a comment, sign in
-
Did you know that 6% of the nearly 7 million Americans living with Alzheimer’s begin experiencing symptoms before the age of 65–with some being affected as early as their 30’s and 40’s? Join our conversation and live Q&A on April 18 with Alzheimer’s expert Dr. Gil Rabinovici to explore how early-onset is recognized, diagnosed, and treated and what separates it from the most common form of the disease. To register, visit: https://lnkd.in/gJzxjv5S #Alzheimers #Health #Neurology
Zoom in on Dementia & Alzheimer's | BrightFocus Foundation
brightfocus.org
To view or add a comment, sign in
-
In Alzheimer's research, new individual pieces are constantly being added to a large puzzle. The amyloid hypothesis, which has dominated for decades, remains at the forefront of scientific efforts to develop effective treatments. However, other causes of these complex diseases are also increasingly being discussed and a variety of other treatment options - including those that can be combined and personalized - are coming onto the scene. In recent days, for example, new studies have been conducted on the active ingredient Semaglutide, which is used to treat diabetes and obesity and is now building a bridge between the treatment of metabolic diseases and neurodegenerative diseases such as Alzheimer's. There is also a new perspective in research into the causes of the disease: British researchers have now been able to show that Alzheimer's can also be transmitted from person to person - under rare and specific conditions. Physical therapies are also increasingly demonstrating that Alzheimer's can no longer be successfully treated with certain drugs alone: So-called NIBS (non-invasive brain stimulation), which includes shockwave therapy Transcranial Pulse Stimulation (TPS), for example, are increasingly proving their benefits and effectiveness in the fight against Alzheimer's. Alzheimer's therapy is therefore in a state of flux: a variety of approaches are now leading to the challenge of using these different treatment approaches as soon as possible and integrating them into everyday medical practice for the benefit of those affected and the healthcare systems. A summary of the topic can be read on "Alzheimer Science": https://lnkd.in/df97Yd22 #alzheimerscience #alzheimersresearch #alzheimers #dementiaresearch #alzheimersdementia #alzheimersdisease #semaglutide #semaglutidealzheimers #alzheimerstransferable #alzheimerssstudies #noninvasivebrainstimulation #nibs #transcranialpulsestimulation #tps #newalzheimerstreatment
To view or add a comment, sign in
-
Developing safe innovative digital health products | Digital Health Consultant | CMO | Health Education | GP | Democratising healthcare | Medical Director | GMC (🇬🇧) and IMC (🇪🇺) Registered
An accurate blood test for Alzheimer's disease! 🧠 The field of Alzheimer's research has reached a significant milestone with a study in JAMA Neurology introducing a plasma-based test for detecting phosphorylated tau 217 (p-Tau217). This method, less invasive than existing testing of cerebrospinal fluid, and cheaper than PET scans in specialist centres, enables early detection for a broader cohort of patients by making it more accessible in terms of location, cost and test acceptability. This innovation represents more than just a diagnostic tool for Alzheimer's; it signifies a global shift in our approach to healthcare. By incorporating these biomarkers into regular health screenings, we can revolutionise preventative medicine, offering hope for early intervention in various diseases. This benefits the patients (improved health outcomes) and state healthcare systems (early intervention usually equals reduced costs). Clinical assessment will never be replaced by testing along, but this paper notes that in primary care >50% of patients with cognitive impairment remain undiagnosed or incorrectly diagnosed because of the lack of accessible and cost-effective tools. The dementias are notoriously difficult to diagnose, so we must celebrate this breakthrough. As access to testing increases, we should look at ways to responsibly utilise these tests within the ecosystem of healthcare. What does this mean? Ensuring that clinicians or patients ordering any test, and patients receiving any test, know the significance, and limitations, of the test and their results. Link to the research paper in the comments. #AlzheimersResearch #democratisinghealthcare #ptau217 #AlzheimersResearchUK #Alzheimers
To view or add a comment, sign in
-
Chief Communications Officer, STEM NOLA | STEM Global Action • Board Chair, Alzheimer's Association Louisiana Chapter [21.4K+ micro-influencers]
Approximately 32 million people globally suffer from Alzheimer's disease, a form of dementia causing memory loss and cognitive issues. Currently, there is no cure for Alzheimer's, but medications are available to manage symptoms and potentially slow disease progression. Researchers from Amsterdam University Medical Centers and Maastricht University have identified five biological variants directly linked to Alzheimer's disease, which may influence future treatments. The study, published in the journal Nature Aging, explored over 1,000 proteins in the cerebrospinal fluid of 419 Alzheimer's patients, revealing distinct subtypes with unique characteristics. The identified subtypes include abnormal outgrowth of nerve cells, an overactive immune system, problems with protein synthesis (RNA metabolism dysfunction), damage in the choroid plexus (organ producing cerebrospinal fluid), and leakage of the blood-brain barrier. These findings challenge previous assumptions and may reshape the development and prescription of Alzheimer's medications. Researchers believe that recognizing these subtypes is crucial for tailoring treatments to specific characteristics, potentially improving the effectiveness of interventions. The study is seen as a hopeful step toward personalizing brain healthcare interventions for Alzheimer's patients. #Alzheimers #BrainHealth #MedicalResearch #Dementia #HealthcareInnovation https://lnkd.in/gA4q43jz
Alzheimer's: Discovery of 5 variants may improve treatment approach
medicalnewstoday.com
To view or add a comment, sign in
-
In Alzheimer's research, new individual pieces are constantly being added to a large puzzle. The amyloid hypothesis, which has dominated for decades, remains at the forefront of scientific efforts to develop effective treatments. However, other causes of these complex diseases are also increasingly being discussed and a variety of other treatment options - including those that can be combined and personalized - are coming onto the scene. In recent days, for example, new studies have been conducted on the active ingredient Semaglutide, which is used to treat diabetes and obesity and is now building a bridge between the treatment of metabolic diseases and neurodegenerative diseases such as Alzheimer's. There is also a new perspective in research into the causes of the disease: British researchers have now been able to show that Alzheimer's can also be transmitted from person to person - under rare and specific conditions. Physical therapies are also increasingly demonstrating that Alzheimer's can no longer be successfully treated with certain drugs alone: So-called NIBS (non-invasive brain stimulation), which includes shockwave therapy Transcranial Pulse Stimulation (TPS), for example, are increasingly proving their benefits and effectiveness in the fight against Alzheimer's. Alzheimer's therapy is therefore in a state of flux: a variety of approaches are now leading to the challenge of using these different treatment approaches as soon as possible and integrating them into everyday medical practice for the benefit of those affected and the healthcare systems. A summary of the topic can be read on "Alzheimer Science": https://lnkd.in/de8JqUKM #alzheimerscience #alzheimersresearch #alzheimers #dementiaresearch #alzheimersdementia #alzheimersdisease #semaglutide #semaglutidealzheimers #alzheimerstransferable #alzheimerssstudies #noninvasivebrainstimulation #nibs #transcranialpulsestimulation #tps #newalzheimerstreatment
To view or add a comment, sign in
-
If you believe untreated concussion and Long COVID are potential risk for neurodegenerative disorders and chronic neuroinflammation. If you believe the research on glymphatic brain "rinsing" is the future for neurodegenerative prevention. Knowing nearly all recovery is at night, knowing inspiration (not exhalation) is the largest driver of CSF hydrostatic shifts, knowing rhythmic oscillations are important in glymphatic drainage, knowing HRV is a whole health biomarker, knowing HRV oscillatory breathing practice during the day improves night time HRV, then you may find this publication in the prestigious journal Nature interesting. The evidence based starting point for Autonomic Rehabilitation is not Navy Seal Box Breathing, Dr. Weil 4-7-8 breathing, meditation, physiological sighs or exercise. The evidence based starting point is oscillatory HRV biofeedback breathing with the diaphragm. Countless studies show a practice of 4-8 weeks improves autonomic function (without breath-holds with proper diaphragmatic technique). Why not give everyone access to no risk, low cost remote coaching and remote tracking devices? #autonomicrehabilitation #longcovid #concussion #hrv #dysautonomia #physiatry
Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults - Scientific Reports
nature.com
To view or add a comment, sign in
8,576 followers